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RIASSUNTO 
Introduzione: La sindrome metabolica è un cluster di anomalie metaboliche, che 
comprende insulino-resistenza, alterata regolazione del glucosio, ipertensione, 
dislipidemia, obesità e aumentato rischio di malattia cardiovascolare. L'insulino-
resistenza (IR) è stata collegata ad alterati indici di rigenerazione vascolare, infatti, 
molti dati mettono in relazione la resistenza insulinica al ridotto numero e funzionalità 
delle cellule endoteliali progenitrici (EPC). Fra i molteplici meccanismi molecolari 
implicati vi sono la riduzione dell’attività e biodisponibilità dell’ossido nitrico (NO) e 
l’aumento dello stress ossidativo. Questi aspetti sono legati sia all’anormale 
attività/produzione di fattori di crescita e chemochine che all’alterato signaling 
intracellulare. L’insulino-resistenza altera la via PI3K/Akt/eNOS stimolata 
dall’insulina che sappiamo essere coinvolta nell’angiogenesi, giocando un ruolo 
importante nella riparazione del danno vascolare. Infatti, è stato dimostrato che l’IR, 
attraverso la down regulation della via del segnale PI3/Akt, causa un decremento della 
produzione di NO, il quale regola la motilità cellulare e la mobilizzazione delle cellule 
staminali dal midollo osseo. L’ossido nitrico di derivazione endoteliale, potente 
vasodilatatore endogeno, viene sintetizzato dall’enzima ossido nitrico sintetasi 
endoteliale in una reazione multistep a partire da L-arginina. È stato dimostrato che la 
L-arginina, potenzia l’uptake di glucosio mediato dall’insulina incrementando il flusso 
sanguigno. Alla luce dei dati ottenuti con la supplementazione orale di L-arginina, 
abbiamo pensato ad una diversa somministrazione di quest’amminoacido, sottoforma 
di prodotto alimentare, molto più gradito ai pazienti. Abbiamo pertanto creato un 
biscotto contenente L-arginina (10%), completamente biodisponibile (> 99%), con un 
basso contenuto di carboidrati. Il biscotto è stato ottenuto combinando L-arginina con 
fiocchi di cereali misti, riso soffiato, nocciole e scorza di arancia candita, mediante un 
processo innovativo di aggregazione (sotto brevetto) di assemblamento/sagomatura del 
prodotto. Ogni biscotto (circa 10 g) contiene almeno 1 g di L-arginina. Dati precedenti, 
ottenuti in uno studio pilota su soggetti sani, hanno mostrato che nel biscotto la 
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biodisponibilità di L-arginina è del 100% e che il prodotto alimentare ha un effetto 
benefico sulla funzione endoteliale e vascolare aumentando l'ossido nitrico e il suo 
secondo messaggero, il cGMP. 
Scopo: Questo progetto è uno studio crossover in doppio cieco condotto su soggetti 
obesi con alterata tolleranza al glucosio (IGT) e sindrome metabolica (SM), al fine di 
valutare gli effetti della L-arginina contenuta nei biscotti, rispetto ai biscotti senza L-
arginina, sulla funzione endoteliale, sul signalling insulinico e sulla mobilizzazione 
delle EPCs. 
Disegno dello studio e metodi: Lo studio, durato sette settimane, è stato condotto su 
quindici soggetti obesi con IGT e MS e consisteva nel consumo giornaliero di 6 
biscotti (arricchiti con L-arginina o placebo) divisi in due snack, mattina pomeriggio. Il 
peso e la massa corporea sono stati valutati con bioimpedenziometria. All’inizio e dopo 
ciascun periodo di intervento nutrizionale, sono stati eseguiti l’OGTT e prelievi 
ematici, a digiuno, per l’esecuzione di saggi biochimici e per la separazione di cellule 
endoteliali progenitrici (EPC). Il flusso ematico dell'avambraccio (FBF) e l’iperemia 
reattiva (vasodilatazione endotelio-dipendente) è stata misurata con la 
pletismografia a strain-gauge. Le EPC sono state valutate mediante citofluorimetria. 
L’espressione genica è stata valutata tramite PCR real time. 
Risultati 
Nel gruppo trattato con biscotti arricchiti con L-arginina è stata riscontrata una 
riduzione del peso corporeo, accompagnata da una significativa riduzione della massa 
grassa, con livelli di NOx, cGMP e del flusso sanguigno post-ischemico 
significativamente aumentati rispetto al gruppo trattato con biscotti placebo. Inoltre, il 
trattamento con  L-arginina ha promosso un incremento sia dei livelli di espressione 
genica di eNOS e Akt (nelle EPC), sia dei livelli plasmatici di SDF-1α, VEGF-α, 
MMP-9, SCF, ed una riduzione dei livelli plasmatici di ADMA. 
Conclusioni: 
I risultati dello studio rivelano che il consumo di biscotti arricchiti con L-arginina, per 
14 giorni é utile per migliorare la funzione endoteliale e vascolare,  il metabolismo del 
glucosio, la diminuzione del  peso e della massa grassa in soggetti con IGT e MS. La 
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forza di questo studio è che la perdita di peso riscontrata è stata ottenuta senza l'aiuto di 
un programma di attività fisica strutturata nei volontari sedentari. Inoltre è  stato 
dimostrato che i biscotti arricchiti con L-arginina sono in grado di aumentare 
l’espressione genica di Akt e di eNOS e di migliorare la mobilizzazione e le proprietà 
di differenziazione cellulare, aumentando sia specifici marker periferici sia il numero 
di EPC circolanti. 
 
 
ABSTRACT 
Introduction: Metabolic syndrome is a cluster of metabolic abnormalities, which 
includes impaired glucose regulation, insulin resistance, hypertension, dyslipidemia, 
obesity and increased cardiovascular disease risk. Insulin resistance (IR) has been 
linked with altered indices of vascular regeneration. Abundant data also link the insulin 
resistance with reduced endothelial progenitor cell (EPCs) number and function. 
Among many molecular mechanisms involved, there are reduced nitric oxide (NO) 
bioavailability and oxidative stress, which are both linked with abnormal growth factor 
and chemokine activity and altered intracellular signaling. Insulin-stimulated 
PI3K/Akt/eNOS signaling, which is involved in angiogenesis, playing an important 
role in vascular repair, is impaired in insulin resistance. In fact it has been demonstrate 
that IR, through the down regulation of the signaling pathway PI3K/Akt, causes a 
decrease of NO production, which regulates cell motility and stem cells mobilization 
from bone marrow.  
The endothelium-derived nitric oxide is a potent endogenous vasodilator that plays a 
major role in vascular tone; it is synthesized by the enzyme endothelial nitric oxide 
synthase (eNOS) in a multistep reaction from L-arginine. It has been previously 
demonstrated that L-arginine potentiates insulin-mediated glucose uptake by increasing 
blood flow.  
In light of these data obtained with L-arginine oral supplementation, we considered a 
new way of administration of this aminoacid, that could be more acceptable by 
patients, through an innovative food product containing L-arginine (at least 10%), 
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completely bioavailable (>99%), with a low content of carbohydrates. Recently we 
developed a food product containing L-arginine, as a biscuit. L-arginine enriched 
biscuits were manufactured in a single batch by combining L-arginine with other 
ingredients (mixed cereal flakes, puffed rice, hazelnuts, candied orange peel) by means 
of an aggregation/shaping innovative process (under patenting) based on sonication. 
Each biscuit (about 10 g) contained at least 1 g of L-arginine. Previous data, obtained 
in a pilot postprandial study in healthy subjects, showed a quite complete bio-
availability of L-arginine in the biscuit and beneficial effect on endothelial and 
vascular function by increasing nitric oxide and its second messenger, cGMP.  
Aim: This project is a double-blind crossover study performed in obese subjects with 
impaired glucose tolerance (IGT) and metabolic syndrome (MS), in order to evaluate 
the effects of the L-arginine-enriched biscuits, compared with placebo biscuits, on 
endothelial function, insulin signalling and  EPC mobilization.  
Study design and methods: The study consisted of a 14-day randomized double-blind 
placebo-controlled crossover intervention trial in which 15 obese subjects with IGT 
and MS consumed  6 biscuits (enriched with L-arginine or placebo) divided into two 
snacks, in the morning and in the afternoon..At baseline and at the end of each 
treatment period blood samples were collected after an overnight fast and during 
OGTT for EPC separation and serum/plasma biochemistries and body weight and 
composition were evaluated by bioimpedenziometry. The forearm blood flow (FBF) 
and reactive hyperemia (endothelium-dependent vasodilation) were measured with 
strain-gauge plethysmography. EPCs were evaluated by flow cytometry. Gene 
expression was evaluate by real time PCR. 
Results: In the group receiving L-arginine-enriched biscuits we found a body weight 
reduction, accompanied by a significant reduction in fat mass, higher L-arginine, NOx 
and cGMP levels and post-ischemic blood flow significantly increased compared with 
the group receiving placebo biscuits. Moreover L-arginine enhanced both eNOS and 
Akt mRNA expression levels (in EPCs) and SDF-1α, VEGF-α, MMP-9, SCF 
plasmatic levels, while reduced ADMA plasmatic levels. 
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Conclusion: The study results reveal that consumption of L-arginine-enriched biscuits 
for 14 days was safe and useful for improving endothelial and vascular function, 
glucose metabolism, decreasing body weight and fat mass in subjects with IGT and 
MS. The strength of the present study is that weight loss was achieved without the help 
of a structured physical activity program in the sedentary volunteers. Moreover, we 
demonstrated that the L-arginine-enriched biscuit was able to increase Akt and eNOS 
gene expression and to improve cell mobilization and differentiation properties, by 
increasing both the specific peripheral markers and the number of circulating EPCs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
8 
 
 
1. PREFACE 
 
1.1. METABOLIC SYNDROME 
Definition and brief history  
The metabolic syndrome is a heterogeneous clinical entity, represented by a 
cluster of multiple abnormalities, affecting obesity, especially abdominal obesity, 
insulin resistance, impaired glucose tolerance, dyslipidemia (high triglycerides and low 
HDL cholesterol) and high blood pressure. The prevalence of these alterations is 
different between the genders at different ages and in different ethnic groups. There are 
still few problems related to the definition and diagnosis of metabolic syndrome: the 
proposed components are continuous variables and as far as is necessary to establish a 
cut-off, there is not yet a consensus on the specific values to establish the diagnosis of 
each component; these variables are certainly interrelated, but the pathophysiology of 
their relationship is not yet clearly understood, and still debated whether or not to 
include insulin resistance and diabetes among the components of diagnostic and 
whether to include other variables (such as those related to inflammation or 
coagulation). It was called plurimetabolic syndrome (Avogaro P), metabolic syndrome 
(Haller H), syndrome X (Reaven GM), deadly quartet (Kaplan NM), insulin resistance 
syndrome (De Fronzo RA), The description of the metabolic syndrome and the attempt 
to standardize the diagnostic criteria have a history that dates back to the early '600, but 
that still keeps the lively debate. It was Nicolaes Tulp (1593-1674) first, in Amsterdam, 
to describe a case of syndrome hypertriglyceridemia (Erklens DW). Tulp established 
the link between hypertriglyceridemia and ingestion of saturated fatty acids ("pure milk 
in the blood"), obesity and bleeding tendency. Not only that, he suggested a therapeutic 
approach correctly indicating a reduction in the contribution of saturated fatty acids, he 
also recognized the association between early atherosclerosis and sudden death. About 
250 years later, Morgagni described very clearly the association between visceral 
obesity, hypertension, hyperuricemia, atherosclerosis and obstructive sleep apnea 
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syndrome, long time before the metabolic syndrome and the syndrome of obstructive 
sleep apnea were defined (Morgagni GB). The frequent simultaneous presence of 
obesity, hyperlipidemia, diabetes and hypertension was described in 1977 by Haller et 
al., who first uses the term "metabolic syndrome" and describes the association with 
atherosclerosis (Haller H). Reaven in 1988 introduces the concept of Syndrome X to 
identify the group of disorders relating to the metabolism of glucose and insulin, 
dyslipidemia and hypertension. Reaven suggested that insulin resistance, which causes 
hyperinsulinemia, characterizes this group of disorders and is an important 
cardiovascular risk factor in itself (Reaven GM). It should be noted that Reaven, in his 
description, had not included among the components of the syndrome overweight 
and/or obesity. In 1991, Ferrannini et al. also suggested that this set of disorders was 
determined by insulin resistance and use the term "insulin resistance syndrome" 
(Ferrannini E). A definition of the metabolic syndrome was given by the "WHO 
Working Group on diabetes" in 1998, then amended in 1999, with a list of criteria for 
clinical diagnosis.  
There were different criteria for the definition of metabolic syndrome, in 2001, 
"United States National Cholesterol Education Program Adult Treatment Panel III 
(ATPIII) report" proposed a set of criteria similar to those proposed by the WHO, 
except for the fact that the key component of visceral obesity and insulin instead 
resistance. The ATP III does not find enough evidence to recommend the routine 
measurement of insulin sensitivity or the dose of glucose to two hours post- load, but 
simply includes the determination of fasting blood glucose (NCEP, 2001). This 
definition of metabolic syndrome requires having at least 3 of the following 5 factors:  
-increased waist circumference (≥ 102 cm in men and ≥88 cm in women),  
-hypertriglyceridemia (≥150 mg/dl ),  
-low HDL cholesterol (<40 mg/dl in men and <50 mg/dl in women),  
-hypertension (≥130/85 mmHg or treatment for hypertension)  
-fasting glucose ≥110 mg/dl (or ≥100 mg/dl, as suggested by the panel of 
experts American Diabetes Association in 2003).  
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In addition, ATP III recommends a number of optional measures, such as C-reactive 
protein as a marker of proinflammatory state, and fibrinogen, as a marker of a 
prothrombotic state. However, the 5 criteria and cut-off values and the proposed by 
NCEP -ATP III panel have some problems as well as the criteria of the WHO. These 
criteria represent a consensus of experts and do not reflect a process of evidence-based 
field data, ie observations of epidemiological and take into account the influence for 
example of the breed and the age even more, the individual components of the 
metabolic syndrome. In addition, it is possible that the current criteria undergo changes 
when there will be more evidence on the role of fibrinogen or C-reactive protein, 
which could then be included as diagnostic criteria. In general, studies performed using 
the definitions proposed by WHO and ATP III show that they identify individuals with 
metabolic syndrome with good overlap (Ford ES). However, in 2009 there was an 
update of ATPIII in which fasting glucose levels and waist circumference were lower: 
fasting glucose ≥100 mg/dl and waist circumference ≥ 94 cm in men and ≥80 cm in 
women (Alberti KG). 
Insulin resistance 
The first definition of insulin resistance (IR) was formulated in 1922 by 
Banting and Best, the two researchers that identified insulin, according to which it was 
to be considered an insulin-resistant subject that it needed to produce more than 200 
units of insulin per day to maintain an acceptable metabolic control (Rosenfeld L). 
Only with the acquisition of the measurement techniques of insulin, the IR has 
acquired a pathophysiological characterized more accurately. Berson and co-workers 
first, in the 70s, began to indicate hyperinsulinemia as marker of a condition in which 
they are required higher concentrations of insulin for evoke a physiological response 
(Yalow RS). The concept of IR was further expanded as a result definition of 
molecular biological and pathophysiological actions of insulin. Eventually '70s, Kahn 
defined the IR as any condition in which physiological insulin concentrations produce 
a biological response lower than normal (Kahn CR). Insulin resistance may involve 
several organs and tissues (liver, skeletal muscle and adipose tissue) or a single cell 
type (for example, the skeletal muscle cell) (Wyne KL; Roden M). 
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The gold standard for defining insulin resistance is the euglycemic hyperinsulinemic 
clamp technique. The hyperinsulinemic euglycemic clamp is the reference method for 
measuring tissue sensitivity to exogenous insulin. This complex test is based on 
amount of insulin infusion, for 120 minutes, such as to bring blood levels of the 
hormone, at a constant level of 100 microU/ml. Measuring the amount of glucose 
required to maintain normal blood glucose levels evaluates the ability of glucose 
uptake in the tissues by exogenous insulin. Since this test is difficult to apply on 
epidemiological studies and very expensive, there are other methods of assessment of 
insulin resistance such as Homoeostasis Model Assessment of Insulin Resistance 
(HOMA-IR), an index based on a mathematical model that considers the steady-state 
serum concentrations of fasting glucose and insulin, calculated as: HOMA index = 
(glucose mmol/L*insulin mU/L)/22.5. (Matthews DR)  
 In a single individual the phenomenon may extend to many biological processes, such 
as the glucose regulation, lipid and protein metabolism, or to be limited to a few 
hormonal actions, such as regulation of glycogen synthesis and/or glucose oxidation.  
Glucose metabolism is the cornerstone of the metabolic actions of insulin, then the IR 
was related to reduced ability of insulin to promote the glucose uptake and a reduced 
lipolysis suppression. The resulting increase in free fatty acids, through a defined 
competition substrate mechanism, even more inhibits the utilization of glucose. This 
creates a vicious cycle that is able to worsen insulin resistance (the Randle cycle) 
(Randle PJ).  According to studies carried out it has been developed by Reaven a 
further definition of IR as a reduced ability to induce consumption of glucose in 
skeletal muscle (44 Reaven GM, 2000). The skeletal muscle, in fact, is responsible for 
70 % of the consumption of glucose in the post- absorptive. Later it was proposed 
additional definitions of IR. In 1991, Flier defined IR as a state in which a given 
concentration of insulin is associated with a subnormal response of glucose metabolism 
(Moller DE). In physiological conditions, insulin stimulates the glucose uptake into 
insulin-dependent target tissues, binding to its receptor on the cell membrane. This 
binding promotes phosphorylation of three tyrosine residues of the insulin receptor 
substrate (IRS-1) located in the cytoplasm. The phosphorylated peptide converts the 
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glicerofosfolipide phosphatidylinositol-4,5-bisphosphate (PIP2) in phosphatidylinositol 
-3,4,5-triphosphate (PIP3) by the enzyme phosphatidylinositol-3-kinase (PI3K), which 
activates in turn the Akt insulin-sensitive protein, also known as protein kinase B. The 
activation of Akt promotes, in metabolic tissues, the translocation of the glucose 
transporter (GLUT 4) to the membrane with consequent intracellular glucose uptake, 
while in endothelial cells the activation of this pathway results in phosphorylation of 
endothelial nitric oxide synthase (eNOS). This enzyme catalyzes the production of 
nitric oxide (NO) which plays a key role in endothelial vasodilation. Therefore, insulin 
resistance is often associated with endothelial dysfunction with impaired 
production/activation of eNOS and NO. 
 Metabolic syndrome and cardiovascular risk 
Metabolic syndrome affects one in five people, and prevalence increases with 
age. Some studies estimate the prevalence in the USA to be nearly 25% of the 
population (Park YW). Subjects with metabolic syndrome have high risk to develop 
type 2 diabetes mellitus and have greater risk of mortality for cardiovascular disease 
(Lakka HM). Several epidemiological studies have identified an increased 
cardiovascular disease risk in individuals with MS (Isomaa B). Insulin resistance, 
metabolic disorders and vascular alterations are often present in individuals affected by 
visceral obesity: this condition, therefore, gives to these individuals an high 
cardiovascular risk (Lebovitz HE). Metabolic syndrome is gradually asserting, among 
the factors that can promote atherosclerosis, as one of the leading causes for 
cardiovascular events, the primary cause of death in industrialized countries. 
Cardiovascular diseases are among the chronic degenerative diseases with the highest 
morbidity and a leading cause of disability. 
Recent epidemiological studies have shown the reversibility of risk, ie the possibility 
of reducing or delaying the onset of events through the reduction of risk factors. 
Mortality and disability that can cause these diseases are the reasons why people 
devote a large space for public health to prevent them. 
1.2 ENDOTHELIAL PROGENITOR CELLS  
Definition 
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The endothelial progenitor cells (EPCs) are a population of circulating cells, derived 
from bone marrow, functionally and phenotypically distinct from adult endothelial 
cells, with clonal expansion ability (ability of a single cell to multiply), proliferative 
and differentiative capacity. They play an important pathophysiological role: in fact 
they increase angiogenesis through the secretion of growth factors, constitute a rich 
source of circulating progenitor cells, are involved in the processes of tissue ischemia, 
in atherosclerosis, in endothelial dysfunction and in the tumor vasculature. 
In 1997, Asahara and collaborators identified for the first time a population of 
circulating cells with properties similar to those of embryonic angioblasts, however 
able to differentiate ex vivo into an endothelial phenotype. These cells were defined 
Endothelial Progenitor Cells (Asahara T). 
The importance of this discovery lies in exceeding the paradigm that postnatal 
neovascularization is mediated exclusively by the proliferation and remodeling of 
mature endothelial cells from pre-existing vessels. In fact, the work of Asahara et al 
has confirmed the crucial role of EPCs in the maintenance of endothelial function of 
blood vessels through a continuous process of re-endothelialization and 
neovascularization (Heiss C). This process consists of several stages characterized by 
the production of specific molecular factors: mobilization of EPCs from bone marrow, 
adhesion and transmigration in the endothelium, chemotaxis - migration - invasion and 
differentiation into mature endothelial cells. The failure/dysfunction of one or more of 
these stages causes a decreased or absent activity of EPCs. However, the normal range 
for the number of circulating EPC in healthy subjects, has not yet been defined. 
There are two different approaches for the identification and characterization of EPCs: 
the flow cytometric technique and the cell cultures.  
The flow cytometric technique is based on the identification of EPCs through the 
evaluation of the surface antigen expression: stem cell and mature endothelial 
differentiation markers. This method has the advantage of being able to select a more 
homogeneous population of cells and to be able to identify multiple cell subsets 
simultaneously, but it is, however, complicated by the absence of unique and restrictive 
markers to the alleged EPCs, given the co-expression of surface antigens than those 
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expressed on the circulating hematopoietic cells and endothelial cells. Another 
important restriction of the flow cytometric method is the lack of information of the 
functional type. The ex vivo approach (cell cultures), in contrast, not only allows the 
identification and the evaluation of EPC number, but also provides information of the 
functional type. This method is based on the EPC isolation from the circulating 
mononuclear cells from peripheral blood and the assessment of their proliferative 
capacity (ability to form colonies, CFU), and differentiative ability into mature 
endothelial cells. 
Origin and differentiation of EPCs 
EPCs derived from the bone marrow hematopoietic stem cells (HSCs) and therefore 
express specific surface markers characteristic of stem cell such as CD133 and CD34. 
In the process of differentiation EPCs acquire early endothelial markers such as 
vascular endothelial growth factor receptor-2 (VEGFR-2), also known as kinase insert 
domain receptor (KDR) Progressively there is a loss of CD133, earlier stem cell 
marker, which leads to a subpopulation of EPCs with the phenotype CD34/KDR. 
There are different phenotypes (CD34/CD133/KDR, CD133/KDR and CD34/KDR) 
that identify the population of EPCs, they have short half-lives, so they are transient 
and detectable even at the same time in the bloodstream. 
The differentiation process gradually leads to the outline Circulating Endothelial Cells 
(CECs) characterized by the expression of mature endothelial markers such as CD31 
(or PECAM-1, platelet cell adhesion molecule-1), VE- cad (vascular endothelial 
cadherin) and the vonWillebrand factor (vWF) accompanied by the loss of stem cell 
markers. In the processes of differentiation of CECs in mature endothelial cells (ECs), 
we are witnessing a high expression of all the specific markers of endothelial cells 
which line: VE -cadherin, vWF, endothelial nitric oxide synthase, CD146 and E -
selectin. 
Insulin resistance and vascular repair  
Insulin resistance is a metabolic disorder which results in the impaired glucose 
homoeostasis, encountered in several conditions, including obesity, pre-diabetes and 
Type 2 diabetes mellitus. Insulin resistance is associated with impaired downstream 
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signal transduction when insulin binds to its receptor, so reducing glucose uptake in 
metabolic tissues. However, the metabolic effects of these molecular abnormalities 
have wider implications than disordered blood glucose regulation alone: dyslipidaemia, 
inflammation and a pro-thrombotic tendency are also hallmarks of insulin-resistant 
states (Hsueh W). The combined effect of these factors in insulin-resistant subjects 
results in a significantly increased risk of cardiovascular events (Booth GL, Cubbon 
RM, Grundy SM). 
Although many questions remain regarding the natural history of atherosclerosis, it is 
commonly accepted that dysfunction of the vascular endothelium represents the earliest 
manifestation of the disease (Ross R). A closely coupled relationship between insulin 
resistance and endothelial dysfunction is now supported by a wealth of observational 
and mechanistic studies. In health, the damaging effects incurred through exposure to 
risk factors are mitigated by endogenous processes which regenerate damaged 
endothelium and preserve the structural and functional integrity of the endothelial 
monolayer (Dimmeler S).  Mature endothelial cells have a finite proliferative capacity 
and have limited potential for repair. The discovery of EPCs by Asahara et al. 
stimulated intense interest in the role of these cells both in terms of new vessel 
formation and in the regeneration of damaged endothelium. Mobilization of EPCs from 
the bone marrow into the circulation occurs in response to growth factors and 
cytokines, including VEGF (vascular endothelial growth factor) and SDF-1α (stromal-
cell-derived factor-1α), (Aicher A). Both VEGF and SDF-1α up-regulate bone marrow 
MMP-9 (matrix metalloproteinase-9) activity. 
The correct process of EPC mobilization/proliferation comprises a cascade of different 
signals, the key role is played by the PI3K\Akt pathway as the phosphorylation of Akt 
leads to activation of eNOS in the stromal cells of the bone marrow resulting in the 
production of nitric oxide. It promotes the transformation of MMP-9 from the inactive 
to an active form; causing the detachment of the SCF (stem cell factor, also known as 
Kit-L, tyrosine-kinase receptor) from the membrane (mKit-L) to form the soluble SCF 
(sKit-L). It acts at the niche of the bone marrow where there are the endothelial 
progenitor cells and promotes their mobilization and diffusion in the blood vessels. 
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After mobilization into the circulation, EPCs home or migrate toward regions of 
endothelial injury, where they adhere and proliferate facilitating vascular repair. 
Chemokine signalling plays a major role in directing circulating progenitor cells to 
sites of injury. Up-regulation of SDF-1α in ischemic tissues is driven largely by tissue 
hypoxia (Ceradini DJ). Interaction between SDF-1α and CXCR4 (CXC chemokine 
receptor 4) then facilitates homing of EPCs to sites of injury. EPCs contribute to 
endothelial repair by two principal mechanisms: by proliferating to form new 
endothelial cells, or by releasing an array of pro-angiogenic cytokines and growth 
factors which stimulate the proliferation of other EPCs or local mature endothelial cells 
(Hur J; Sieveking DP). 
Disorders of glucose regulation are associated with abnormalities in EPC biology, 
including reduced circulating numbers of EPCs, defective mobilization from bone 
marrow and impaired functional properties of EPCs implicit to their capacity to 
mediate endothelial repair. Flow cytometric and cell culture analyses demonstrate 
consistently fewer circulating EPCs across the spectrum of insulin-resistant states. 
Individuals with Type 2 diabetes have reduced levels of circulating EPCs, which are 
correlated with disease severity (Tepper OM, Egan CG; Fadini GP, 2005; Kusuyama 
T). Hyperglycaemia may partially explain this association, as Fadini et al. (Fadini GP, 
2007) demonstrated reduced numbers of EPCs in individuals with impaired glucose 
tolerance compared with those with normal glucose regulation. EPCs were negatively 
correlated with glucose levels after a glucose challenge. EPCs were, however, 
negatively correlated with components of the metabolic syndrome and with HOMA-
IR, in a separate study of subjects across a wide range of cardiovascular risk (Fadini 
GP, 2006). EPCs were also found to be lower in another study of obese men with the 
metabolic syndrome compared with non-obese healthy controls (Westerweel PE). In 
that study, EPCs were associated with BMI (body mass index) and correlated inversely 
with components of the metabolic syndrome, but insulin resistance was not studied 
separately. Reduced circulating EPCs may be attributable to a number of factors, 
including defective mobilization, decreased proliferation and shortened survival in the 
circulation (Aicher A, 2003; Aicher A, 2004; Hristov M). As discussed in further detail 
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below, insulin resistance is closely associated with abnormalities in NO bioavailability 
and PI3K/Akt signalling, both of which play a crucial role in EPC mobilization from 
the bone marrow (Aicher A, 2003; Hristov M; Dimmeler S; Thum T; Werner C; Urao 
N). EPCs from humans and animals with Type 2 diabetes have multiple functional 
defects in vitro, including impaired migration to chemotactic stimuli, reduced 
proliferative potential and diminished ability to form vascular-like structures, which 
are likely to limit their regenerative capacity (Tepper OM; Ii M). These functional 
deficits appear to be biologically relevant in vivo, as Ii et al. (Ii M) have demonstrated 
that re-endothelialization following endothelium-denuding injury was impaired in mice 
with Type 2 diabetes (Ii M). Unfortunately, such studies do not allow the effects of 
insulin resistance to be considered separately from those of hyperglycaemia and other 
metabolic derangements characteristic of diabetes. Homing of EPCs to sites of vascular 
injury is dependent on an interaction between locally produced chemokines and the 
CXCR4 receptor on EPCs. Diabetes is associated with a decreased expression of the 
chemokine SDF-1α in injured tissues (Badillo AT) and reduced expression of CXCR4 
in peripheral mononuclear cells (Egan CG), which may inhibit recruitment of EPCs 
from the circulation. 
1.3 ENDOTHELIAL FUNCTION 
Endothelium 
The endothelium is a ubiquitous organ responsible for the regulation of 
hemodynamic and metabolic processes and it is also involved in the synthesis and 
inflammatory processes. The endothelial cells occupy an important position between 
the blood and the tissues; this location facilitates their involvement in numerous 
physiological processes; these cells are very thin and closely linked to each other, so 
that the endothelial surface does not present any discontinuity (except for sinusoids); 
typically, they assume an elongated shape towards the direction of blood flow, 
especially in the arterial vessels of greater caliber; in the capillaries, they are 
characterized by the extreme thinness. The endothelium is not a simple inner lining of 
the vessels but it is considered a real organ composed by one trillion cells that together 
weigh as the liver. The endothelium can be considered an autocrine and paracrine 
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organ able to secrete, in response to a large variety of signals, numerous chemical 
mediators that influence either the same cells that produced them that those nearby. 
The result is a modulation of vascular tone and blood flow in response to nervous, 
humoral and mechanical stimuli. The endothelial functions are several and very 
complex (and even more numerous are the mediators produced by its cells): 
• Barrier function: the endothelium is similar to a semi-permeable membrane that 
controls the passage of substances from the extracellular fluid to bloodstream and vice 
versa; 
• Regulation of coagulation, fibrinolysis and platelet aggregation; blood fluidity 
balance 
• Control of leukocyte adhesion and infiltration 
• Control of the proliferation of smooth muscle cells of the tunica media; modulation of 
tone, vascular permeability and structure; it plays a major role in the remodeling 
observed in hypertension, in re-stenosis after percutaneous coronary intervention and 
in the atherosclerosis 
• Formation of new blood vessels (angiogenesis) 
• Oxidation of LDL and regulation of inflammatory processes 
The chemical mediators produced by the endothelium can be distinguished in 
vasodilators, which increase the lumen of the vessels with anti-proliferative, anti-
thrombotic and anti-atherogenic action, and vasoconstrictors, which instead have 
opposite function. 
Nitric oxide (NO) is the most important mediator of normal endothelial function: it is a 
potent vasodilator and it inhibits platelet activation, smooth muscle cell migration and 
proliferation, and leukocyte adhesion and activation. Consequently, the altered nitric 
oxide production has been associated with vascular diseases such as atherosclerosis, 
diabetes or hyperlipidemia. Endothelial dysfunction is characterized by an irregular 
secretion of nitric oxide and a resistance in states of abnormal insulin resistance. 
Nitric Oxide 
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The nitric oxide is a bioactive product produced by several types of 
mammalian cells, with the lowest molecular weight among all cellular mediators 
known (Nathan C). 
It is an intra and extracellular mediator virtually ubiquitous involved in several 
pathophysiological processes such as neurotransmission, inflammatory response and 
immune vascular homeostasis. It is produced by many cell types, including endothelial 
cells, monocytes, macrophages and neurons. The predominant effect of nitric oxide 
depends on the site production, the magnitude of its output and the type of target tissue. 
The biological half-life is a function of oxygen tension and the superoxide anion 
concentration and caries directly with the gas concentration in the solution. We 
consider that a NO concentration of 10-50 nm has a half-life of 3-5 sec, while a 
concentration of 300 nm has a half-life of 30 seconds (Ignarro LJ). Currently, nitric 
oxide is used as a mediator of numerous cell functions, including the following:  
(Sheferd JT; Stuehr DJ) 
-vascular and intestinal smooth muscle, arterial and venous vasodilation,      
  peristalsis inhibition  
- platelet aggregation and adhesion inhibition  
- cell proliferation inhibition  
- immunomodulatory and cytotoxic effect of macrophages, polymorphonuclear  
  cells, lymphocytes and other cells involved in immune defence  
- neurotransmission  
- mutagenicity 
Mechanisms of action of Nitric Oxide 
The vasodilation, antiaggregant and neuromodulatory actions of NO are due to the 
stimulation of a soluble guanatocyclase in the smooth muscle vascular cells, in 
platelets, neurons and other cells. The binding to guanylyl cyclase cause a change in its 
conformation with activation of catalytic site which follows an increase of ATPasi Na-
K activity and an increase of cGMP synthesis from guanosintriphosphate. Two 
guanylyl cyclase isoforms are present, one cytosolic or soluble, activate by NO and the 
other one bind to the membrane, activate by atrial natriuretic peptide. The soluble 
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guanylyl cyclase is an eterodimeric protein of 150 kDa, containing a heme mole and 
one Cu++ for dimero mole (Ignarro LJ).  The nitric oxide affinity constant for heme is 
3000 times greater than oxygen. Paramagnetic NO binds with high affinity to the Fe++ 
heme hemoprotien, forming a nitrosil-heme adduct more stable than NO (Nathan C). 
On the other side, NO rapidly reacts with oxygen and free radicals derivates, as 
superoxide anion: this explains the protective effect of superoxidedesmutase on NO 
activity. NO binding the heme of soluble guanylyl cyclase, forms a ternary complex 
enzyme nitrosyl-heme, determining an increase of enzyme activity of 50-200 times.  
Nitric oxide synthases  
Nitric oxide is synthesized from guanidine nitrogen of L-arginine, which then gives 
rise to nitric oxide and L-citrulline. This reaction is catalyzed by a family of enzymes 
called NO synthase (NOS) (Forstermann U). Nitric oxide synthase can be present in 
plasma membrane, cytoplasm, nucleus, rough endoplasmic reticulum and mitochondria 
of cells. There are three isoforms of the NOS: nNOS (type 1 NOS), which was first 
discovered in neuronal tissues; iNOS (type 2 NOS), which was originally found to be 
inducible under certain conditions in macrophages and hepatocytes and eNOS (type 3 
NOS), which was first identified in endothelial cells. These NOS isoforms are encoded 
by three different genes, and their nucleotide sequences are 51–57% homologous 
(Alderton WK). In general, eNOS, nNOS and iNOS are localized primarily in plasma 
membrane and cytoplasm, mitochondria and cytoplasm, and cytoplasm, respectively; 
nNOS and eNOS are expressed constitutively at low levels in a variety of cell types 
and tissues, whereas iNOS is normally not expressed at a significant level in cells or 
tissues (17 Wu G). When induced by certain immunological stimuli (including 
inflammatory cytokines or bacterial endotoxin), iNOS is highly expressed in many cell 
types and produces a large amount of NO. Due to its high affinity for calcium and tight 
binding with calmodulin, iNOS is fully active in the absence of exogenous Ca2+ or 
calmodulin. All of the NOS isoforms can be induced under certain stimuli through 
transcriptional and translational mechanisms (Wu G, 1998). Structurally, all NOS 
isozymes are homodimers. In functional NOS, the C-terminal reductase domain of one 
monomer (with binding sites for NADPH, FMN, and FAD) is linked to the N_terminal 
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oxygenase domain of the opposite monomer. This oxygenase domain carries a 
prosthetic heme group. The oxygenase domain also binds the tetrahydrobiopterin 
(BH4), molecular oxygen, and the substrate L-arginine. In a first step, NOS 
hydroxylates L-arginine to NG-hydroxy-L-arginine. In a second step, NOS oxidizes 
NG-hydroxy-L-arginine to citrulline and NO, (image 1) (Griffith OW).   
 
Image 1: Schematic representation of  the NO synthesis reaction (Daff S Nitric Oxide 
23,2010) 
 
Compelling evidence shows that NO synthesis is regulated not only by the amount 
and/or phosphorylation of the NOS protein, but also by the availability of cofactors 
(particularly NADPH, BH4 and Ca2+) and Arginine (image 2). (Wu G, 2002). 
Although the Km values of NOS for Arginine are 3 to 20 µM, depending on its 
isoform, increasing extracellular Arginine concentrations from 0.05 to 5 mM dose 
dependently increases NO synthesis in a variety of cells, including activated 
macrophages and endothelial cells (Wu G, 1998). It is clear that Arginine increases the 
transcription of iNOS in macrophages and BH4 synthesis in endothelial cells (Shi W) 
whereby Arginine stimulates NO production in both cell types.  
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Image 2: endothelial nitric oxide synthase with ist substrate and cofactors. 
(Forstermann U Eur J Physiol 459, 2010) 
 
L-arginine 
L-arginine (2-amino-5-guanidino-pentanoic acid) is a conditionally essential, 
proteinogenic amino acid that is a natural constituent of dietary proteins. L-arginine is a 
basic amino acid (AA) in physiological fluids. Besides its role in protein metabolism, L-
arginine is involved in various metabolic pathways, such as synthesis of creatine, L-
ornithine, L-glutamate, and polyamines. Decarboxylation of L-arginine can produce 
agmatine, a biogenic amine metabolite. L-arginine is also involved in protein 
degradation by the ubiquitin-proteasome pathway. A biologically important pathway 
involves L-arginine as the substrate of a family of enzymes named nitric oxide 
synthases. The reaction mechanism of NO synthases involves a 2-electron transfer from 
molecular oxygen via a number of cofactors to L-arginine, resulting in the release of 
NO and L-citrulline (Wu G, 2009). 
Its content is relatively high in seafood, watermelon juice, nuts, seeds, algae, meats, 
rice protein concentrate, and soy protein isolate (King DE), but low in the milk of most 
mammals (including cows, humans, and pigs) (Wu G, 1994). Results of the third 
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National Health and Nutrition Examination Survey indicate that mean Arginine intake 
for the US adult population is  4.4 g/day, with 25, 20 and 10% of people 
consuming<2.6 (suboptimal), 5–7.5, and>7.5 g/day, respectively (King DE).  
Substantial amounts of orally administered Arginine do not enter the systemic 
circulation in adults, because 40% of dietary Arginine is degraded by the small 
intestine in first pass metabolism (Wu G, 2009).  Although it is often stated that 
Arginine is formed in the mammalian liver, there is no net synthesis of Arginine via the 
hepatic urea cycle because the liver contains an exceedingly high Arginase activity to 
hydrolyze Arginine into urea plus ornithine (Wu G, 1998). Indeed, Arginine 
concentrations in hepatocytes are very low (0.03–0.1 mM), compared with 0.5–10 mM 
for other aminoacids (Li P). In adults, endogenous synthesis of Arginine involves the 
intestinal-renal axis (Wu G, 1998). Namely, citrulline is synthesized from glutamine, 
glutamate and proline in the mitochondria of enterocytes, released from the small 
intestine, and taken up primarily by kidneys for Arginine production. Interestingly, the 
uptake of citrulline by liver is negligible and this organ is not active in extracting 
Arginine from the circulation (Wu G, 2007). Therefore, nearly 100 and 90% of the gut-
derived citrulline and Arginine, respectively, bypass the liver in pigs (Wu G, 2007). 
Similar patterns of citrulline and Arginine metabolism have recently been reported for 
humans (Van De Poll FW). Pyrroline-5-carboxylate (P5C) synthase, proline oxidase, 
and N-acetylglutamate (NAG) synthase are the three key regulatory enzymes of 
intestinal citrulline synthesis (Wu G, 1998). The enterocyte is the only mammalian cell 
type that expresses all three of these enzymes, indicating an essential role for the gut in 
whole-body homeostasis of citrulline and Arginine (Flynn E). In mammals, when 
dietary levels of Arginine are high, intestinal synthesis of citrulline from glutamine and 
glutamate may be inhibited for sparing of glutamine and glutamate for other metabolic 
pathways. Besides the kidney, citrulline is readily converted into Arginine in nearly all 
cell types, including adipocytes, endothelial cells, enterocytes, macrophages, neurons, 
and myocytes (Wu G, 1998).  
Studies with macrophages and endothelial cells demonstrated that citrulline is 
transported into cells by the N system which is selective for aminoacids with a side-
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chain amide group (e.g., glutamine and asparagine). Inside cells, conversion of 
citrulline into Arginine via Argininosuccinate synthase and lyase is the only pathway 
for citrulline utilization (Wu G, 1998).  
Arginine transport by cells involves the system y+ (a high-affinity, Na+-independent 
transporter) and Na+ dependent transporters (e.g., b0+, B0+, and y+L) in a cell-specific 
manner (Grillo MA). The system y+ is the principal high-affinity cationic amino acid 
transport (CAT) system expressed in NO-producing cells that transports arginine from 
the blood circulation into cells. Besides system y+, systems y+L, b0+, and B0+ have 
been characterized for transport of a wider range of substrates including cationic and 
neutral amino acids.  
In endothelial cells, transport of L-arginine and other cationic amino acids is mediated 
principally via the Na+-independent cationic amino acid transport systems y+ and y+ L, 
with negligible entry mediated by Na+-dependent or Na+-independent transport systems 
B0+ or b0+, respectively, or passive diffusion. 
 Within the y+ system, 4 related CAT proteins are identified (CAT1 to CAT4), with 2 
variants of CAT2, namely CAT2A and CAT2B. The CAT isoforms are the main 
transporters of L-arginine across the cell membrane. CAT-1, CAT-2A, and CAT-2B 
are located in the plasma membrane, with CAT-1 being expressed ubiquitously (except 
for adult liver hepatocytes), CAT-2A being predominantly expressed in the liver, and 
CAT-2B usually induced under inflammatory conditions in various cells. CAT-3 is 
specifically expressed in the brain, whereas CAT-4 is designated by a cDNA in human 
placenta. In a quiescent state, intracellular arginine transport is mostly through the 
CAT-1 transporter. Arginine uptake in activated macrophages is increased through 
induction of the CAT-2 transporter once inside cells; there are multiple pathways for 
Arginine degradation to produce NO, ornithine, urea, polyamines, proline, glutamate, 
creatine, and/or agmatine (Wu G, 1998). These pathways are initiated by Arginase, 
three isoform of NOS, Arginine:glycine amidinotransferase, and Arginine 
decarboxylase. Quantitatively, 1-2% of metabolized Arginine are utilized for 
polyamine synthesis and constitutive NO production, respectively, in mammalian cells 
(Li H, 2001). In mammals, the Arginase pathway is quantitatively most important for 
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Arginine catabolism. Type-I Arginase is expressed abundantly in hepatocytes (Morris 
SM) and to a limited extent, in extrahepatic cells, including enterocytes of post 
weaning mammals, endothelial cells, mammary epithelial cells, macrophages, and red 
blood cells (only in primates) (Li H, 2001). In contrast, type-II Arginase is widely 
expressed at relatively low levels in virtually all mitochondria-containing extrahepatic 
cells (including neuronal, renal, vascular, and muscle cells) and plays an important role 
in regulating the synthesis of NO, proline and polyamines (Li H, 2002). Large amounts 
of Arginine (2.3 g/day in a 70 kg man) are utilized for the production of creatine via 
the interorgan cooperation of kidneys, pancreas, liver and skeletal muscle.   
There is a complex compartmentalization of Arginine degradation at cellular, tissue, 
and whole-body levels, and dietary Arginine supplementation may be a necessary 
strategy to maintain Arginine homeostasis for good health and body functions under 
many physiological and pathological conditions (Wu G, 2009). Arginine metabolism is 
regulated by multiple factors that include dietary components (e.g., lysine, manganese, 
n-3 fatty acids), hormones (e.g., glucocorticoids, growth hormone, and leptin), 
cytokines, endotoxins, and endogenously generated substances (e.g., creatine, lactate, 
ornithine, P5C, and methylarginines).  
Lysine competes with Arginine for entry into cells and also inhibits Arginase activity 
(Wu G, 1998). Therefore, the dietary Arginine:lysine ratio is a critical factor 
influencing the effect of Arginine supplementation. Under normal feeding conditions, 
the total amount of Arginine in the diet should not be 150% greater than that of lysine 
(namely, Arginine/lysine<2.5). It is of interest to notice that these two dibasic 
aminoacids have a rate of entry into the brain proportional to its own concentration in 
the blood throughout a range of normal levels. However when the blood concentration 
of either of these aminoacids was raised above physiological levels the rate of entry 
ceased to be proportional to the blood concentration and increased less rapidly than at 
lower levels. In addition there is an inhibition of the entry of L-arginine into the brain 
if the concentration of l-lysine is raised to levels above the physiological and in the 
same way when L-arginine concentration rises up. 
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Modulation of endothelial cell L-arginine transport  
L-arginine transport could be modulated by oxidatively modified low-density 
lipoproteins (LDL) and lysophosphatidylcholine (LPC). At physiological plasma 
concentrations, entry of L-arginine is mediated preferentially via a CAT system. 
Endothelium-derived NO synthesis and/or bioavailability is impaired in atherogenic 
vessels. Lysophosphatidylcholine and oxidized low-density lipoproteins (oxLDL) were 
proposed by Kikuta et al. (314) to inhibit NO production in endothelial cells by 
inhibiting a high-affinity transport system for L-arginine. Increasing extracellular L-
arginine concentrations partially restores NO synthesis, with transport of L-arginine 
mediated preferentially via a low-affinity but high-capacity transport system(s). This 
model proposes that impaired eNOS activity can be restored by increased transport of 
L-arginine via a low-affinity carrier. 
Role of caveolae 
Caveolae are specialized invaginations of the plasma membrane (50–100 nm diameter) 
also known as “lipid rafts” formed as a result of localized accumulation of cholesterol, 
glycosphinogolipids, and structural proteins. The discovery of highly organized 
signalling molecules localized to membrane caveolae, including system y_ (CAT-1), 
eNOS, argininosuccinate synthase, receptors for insulin,  provides an opportunity for 
investigating the role of caveolin-1 in modulating the L-arginine-NO signalling 
pathway in vascular endothelium.  
It is possible to postulate a potential role of plasma membrane caveolae in modulating 
cationic amino transport in vascular endothelial cells. As shown before in endothelial 
cells uptake of L-arginine is mediated principally by systems y+ and y+L, and these 
transporters may be sequestered near or in plasmalemmal caveolae and that systems 
y+L and y+ mediate high-affinity transport of L-arginine. Co-localization of eNOs and 
the systems Y+ in caveolae in part explains the “arginine paradox” related to the 
phenomenon that in certain disease states eNOS requires an extracellular supply of L-
arginine despite having sufficient intracellular L-arginine concentrations. 
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2. STATE OF THE ART 
 
Recently we have published a study to determine whether sucrose-induced insulin 
resistance could increase the expression of cardiac matrix metalloproteinases (MMPs), 
indices of matrix remodelling, and whether the addition of 1.25 g day (-1) of L-
arginine (ARG) to a sucrose diet could prevent both the sucrose-induced metabolic 
abnormalities and elevated cardiac expression of matrix metalloproteinases in an 
insulin resistant stage that precedes frank type 2 diabetes. 38 male Sprague-Dawley 
rats were involved, 16 rats maintained a standard chow diet (ST), 12 rats were switched 
to a sucrose enriched diet (SU) and 10 rats to a sucrose plus L-arginine (1.25 g day (-
1)) enriched diet (SU + ARG) for a period of 8 weeks. After 8 weeks of different diets, 
an intravenous glucose tolerance test (IVGTT) was performed.  At the end of the study, 
retroperitoneal fat, heart weight/body weight ratio, fasting plasma glucose, serum 
insulin, and serum triglyceride levels and integrated insulin area after IVGTT were 
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significantly higher in SU than in SU + ARG and ST. All these parameters were 
comparable between SU + ARG and ST animals. FFA levels were significantly 
different among groups, with highest levels in SU and lowest levels in ST. Fasting 
plasma c-GMP levels and the integrated c-GMP area after IVGTT, an index of nitric 
oxide activity, were significantly lower in SU than in SU + ARG and ST, the result 
was similar in SU + ARG and in ST; MMP-9 protein expression increased 10.5-fold, 
MMP-2 protein expression increased 2.4-fold and the expression of tissue inhibitors of 
metalloproteinase (TIMP-1) increased 1.7-fold in SU rats as compared to ST animals. 
This was accompanied with a significant increase of cardiac triglyceride 
concentrations. SU rats developed insulin resistance and hyperlipidaemia, accompanied 
with increased fat deposition in the heart and enhanced MMP protein expression. 
Conversely, ARG supplementation prevents these metabolic abnormalities and restored 
MMP/TIMP-1 balance (Monti LD, 2008). 
In humans, the intravenous infusion 0.5 g/min of L-arginine but not D-Arginine 
increased whole body glucose disposal, and blood flow in normal subjects (Paolisso 
G). McConnell et al. performed similar amount of L-arginine infusion in endurance 
trained males during exercise test (McConell GK). They found that L-arginine 
determined a significant increase of the whole body glucose disposal, a decrease of free 
fatty acid levels while insulin levels remained unchanged as compared to saline control 
study. These data strongly suggest that L-arginine infusion improved muscle glucose 
utilization modulating free fatty acid concentration during exercise. Insulin sensitivity 
and insulin-mediated vasodilation were also improved by infusing lower doses of L-
arginine (0.52 mg kg-1min-1) in healthy, obese and type 2 diabetic subjects (Washer 
TC).  
These effects were confirmed by a double-blind chronic treatment of L-arginine (9 g 
daily) in non obese type 2 diabetic patients. After one month of L-arginine therapy 
peripheral and hepatic insulin sensitivity were significantly improved and cyclic-GMP 
levels and insulin-mediated vasodilation were normalized (Piatti PM). Recently our 
group has published a clinical trial regarding the specific effect of L-arginine on 
adiposity in humans. This was a 21-day randomized, placebo-controlled trial in 33 
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hospitalized middle-aged, obese (mean BMI = 39.1±0.5 kg/m2) subjects with diet-
controlled Type 2 diabetes mellitus. During the study period, each patient received a 
low-caloric diet (1000 kcal/day) and a regular exercise-training program (4 min twice a 
day for 5 days/week). They were randomized to 8.3 g arg/day (approximately 80 
mg/kg body weight per day) or placebo. As expected from the low caloric diet, both 
groups of subjects exhibited reductions in body weight, fat mass, waist circumference, 
circulating levels of glucose, fructosamine and insulin. Moreover, increase in 
antioxidant capacity and circulating levels of adiponectin were observed for these 
patients. Importantly all improvements were significantly greater in arginine group 
than in the placebo group. Additionally fat free mass was maintained in the L-arginine 
group but reduced by 1.6 kg in the placebo group. Thus, Arginine supplementation to 
obese subjects promoted fat reduction and spared lean body mass during weight loss 
(Lucotti P, 2006).  
We evaluated also the effects of long-term oral L-arginine treatment on endothelial 
dysfunction, inflammation, adipokine levels, glucose tolerance, and insulin sensitivity 
in no diabetic patients with stable cardiovascular disease (coronary artery disease). 
Sixty-four patients with cardiovascular disease previously submitted to an 
aortocoronary bypass and not known for type 2 diabetes mellitus had an oral glucose 
load to define their glucose tolerance. Thirty-two patients with non diabetic response 
were eligible to receive, in a double-blind randomized parallel order, L-arginine (6.4 
g/d) or placebo for 6 months. An evaluation of insulin sensitivity index during the oral 
glucose load, markers of systemic nitric oxide bioavailability and inflammation, and 
blood flow was performed before and at the end of the treatment in both groups. 
Compared with placebo, L-arginine decreased asymmetric dimethylarginine levels 
(p<0.01), and increased cyclic guanosine monophosphate (p<0.01), L-arginine to 
asymmetric dimethylarginine ratio (p < 0.0001), and reactive hyperemia (p<0.05). 
Finally, L-arginine increased insulin sensitivity index (p <0.05) and adiponectin 
(p<0.01) and decreased interleukin-6 and monocyte chemoattractant protein-1 levels. 
In conclusion L-arginine seems to have anti-inflammatory and metabolic advantages in 
these patients (Lucotti P, 2009). An anabolic effect of L-arginine on muscle gain is 
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achieved independent of changes in serum concentrations of insulin or growth 
hormone. Dietary arginine supplementation enhances insulin sensitivity and amplifies 
its signalling mechanisms on protein synthesis as well as the metabolism of glucose 
and fatty acids. So Arginine supplementation regulates the repartitioning of dietary 
energy to favour muscle over fat gain in the body. Recently Monti LD et al. performed 
a mono-centre, randomized, double-blind, parallel-group, placebo-controlled, phase III 
trial (named l-arg trial). In this study, 144 individuals, affected by impaired glucose 
tolerance (IGT) and metabolic syndrome (MS), received 6.4g/day of L-arginine, or 
placebo for 18 months plus a 12-month extended follow-up period after study drug 
termination, in order to prevent or delay type 2 diabetes and to normalize glucose 
tolerance in individuals at high risk for type 2 diabetes. The results showed that the 
supplementation of L-arginine for 18 months does not significantly reduce the 
incidence of diabetes but does significantly increase regression to normal glucose 
tolerance (NGT). (Monti LD, 2012). 
In light of these data obtained with L-arginine oral supplementation, we considered a 
new way of administration of this amino acid, that could be more acceptable by 
patients, through an innovative food product containing L-arginine (at least 10%) with 
a low content of carbohydrates.  
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3. AIM 
 
The use of L-arginine as oral food supplement to a normal diet, in relatively 
large doses, has been proved to have a salutary effect on cardiovascular diseases as 
extensively described in literature, both in animal and in humans studies. L-arginine 
was found to be bioavailable and effective in the prevention of impairment of glucose 
metabolism and endothelial dysfunction, improving endothelial-mediated blood flow.  
In light of these data obtained with L-arginine oral supplementation, we formulated a 
new food product containing L-arginine, designed in the form of biscuit, as an 
alternative to a pharmacological approach; this product containing 10% of L-arginine 
and low levels of glycemic carbohydrates appears to be more palatable and acceptable 
by the subjects with IGT and metabolic syndrome. Previous data, obtained in a pilot 
postprandial study in healthy subjects, showed that in the biscuit enriched of L-arginine 
(6.6 gr in 6 biscuits), the L-arginine bio-availability is >99% and promotes a beneficial 
effect on endothelial and vascular function by increasing nitric oxide and its second 
messenger, cGMP. This PhD project is a double-blind crossover study performed in 
obese subjects with impaired glucose tolerance (IGT) and metabolic syndrome (MS), 
in order to evaluate the effects of the L-arginine-enriched biscuits consumption on 
endothelial function, glucose metabolism and on changes in body composition. 
Moreover we assessed in vitro, the effect of L-arginine on endothelial progenitor cells 
via Akt-eNOS pathway, both as gene expression and as protein expression of the two 
molecules. New peripheral markers of the beneficial effect of L-arginine on the 
modulation of endothelial progenitor cells were also evaluated. 
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4. RESULTS AND DISCUSSION 
 
4.1 MATERIALS AND METHODS 
4.1.1 Formulation of the biscuit 
L-arginine-enriched biscuits were manufactured in a single batch by combining 20% 
L-arginine Kyowa (Eurosup, Castello D'Agogna, PV, Italy) with 26 % mixed cereal 
flakes (corn, oat, whole wheat), 18% puffed rice, 17% hazelnuts, and 17% candied 
orange peel. Biscuits were produced by mixing all ingredients with a minimum of 
water (about 4-8 % of total weight) to support homogenization. Then an 
aggregation/shaping process (patented) was performed by sonication of the mixture, 
using a prototype of sonotrode in titanium (20-40 kHz; Branson); the process was 
conducted at low temperature range, which prevents the degradation of the amino acid 
by Maillard reactions or other heat dependent modifications. A cylindrical mould was 
used to achieve the shape of the food product. The process was maintained for 20-2000 
milliseconds at a starting temperature of 25-40 °C without temperature changes at the 
inner of the product till the end of the sonication process. To increase the shelf life of 
the food product, its water content was successively reduced by a batch drying process, 
at a temperature less than 60 °C in a static oven. The food product, ready to eat, was 
then conveniently packed and stored at room temperature. The resulting product was 
storage stable under normal conditions for an extended period of time. One single unit 
weight was about 10 g and comprises at least 1 g of L-arginine; as evaluated by 
appropriate analogic scale, the product had pleasant organoleptic properties and no 
undesirable after taste has been pointed out. Placebo biscuits without the addition of L-
arginine were similarly formulated and obtained with the same technological process. 
4.1.2  Subjects and study design 
This 7-week study enrolled 15 obese subjects with IGT and MS (8 men/7 women, aged 
62.5±3.5 years) in a randomized double-blind placebo-controlled crossover design. A 
baseline evaluation and oral glucose tolerance test was performed to recruit only 
patients with IGT and MS. The latter was defined according to ATP III, metabolic 
syndrome requires having at least 3 of the following 5 factors:  
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-increased waist circumference (≥ 102 cm in men and ≥88 cm in women),  
-hypertriglyceridemia (≥150 mg/dl ),  
-low HDL cholesterol (<40 mg/dl in men and <50 mg/dl in women),  
-hypertension ( ≥130/85 mmHg or treatment for hypertension),  
-fasting glucose ≥110 mg/dl (or ≥100 mg/dl, as suggested by the panel of 
experts American Diabetes Association in 2003).  
Namely in the presence of one or more risk factors for type 2 diabetes, including 
overweight (body-mass index [BMI] >25 kg/m², family history of type 2 diabetes (first 
degree relatives of patients with type 2 diabetes), and cardiovascular disease. Diagnosis 
of IGT was based on a fasting plasma glucose tests (FPGT) result of less than 7.0 
mmol/L (less than 126 mg/dl) and a plasma glucose value of 7.8 mmol/L (140 mg/dl) 
or more, but less than 11.1 mmol/L (200 mg/dl) 2 h after the 75 g oral glucose load 
(OGTT). OGTTs were also repeated at the end of each intervention period. 
Clinical and metabolic variables of involved subjects are reported in Table 1.  
Age (years) 62.5 ± 3.5
Gender M:F 8 : 7
Weight (kg) 84.5 ± 4.2
BMI (kg/m2) 30.3 ± 1.5
Fat Mass (FFM, kg) 29.6 ± 3.0
Free Fat Mass (FM, kg) 62.5 ± 3.5
Waist (cm) M: 108.8 ± 4.0/ F: 102.0 ± 4.3
Systolic Blood Pressure (mmHg) 121.3 ± 4.0
Diastolic Blood Pressure (mmHg) 76.0 ± 2.0
Fasting glucose levels (mg/dl) 113.2 ± 3.5
Fasting insulin levels (µU/ml) 9.4 ± 2.0
Total cholesterol levels (mg/dl) 160.0 ± 9.1
HDL cholesterol levels (mg/dl) 43.4 ± 3.1
Trigliceride levels (mg/dl) 96.3 ± 13.4
NOx (µmol/l) 17.9 ± 2.8
cGMP (pmol/mL) 7.4 ± 0.9
Basal forearm blood flow (ml/100 ml/min) 2.98± 0.24
Post-ischemic forearm blood flow (ml/100 ml/min) 5.73 ± 0.63
 
Table 1: Clinical and metabolic characteristics of the 15 participants of this study  
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Patients were randomized into two groups. One group consumed 6 biscuits containing 
a total amount of 6.6 g of L-arginine divided into two snacks (in the morning and in the 
afternoon) for 2 weeks, followed by the consumption of 6 placebo biscuits for 2 weeks, 
with a 2-week washout between the two study periods. The other group consumed 
these food preparations types in reverse sequence.  
During each two-week intervention period the amount of energy derived from the 
biscuits (180kcal) was included in a 1600cal balanced hypo caloric diet containing 
55% carbohydrate, 25%–30% fat and 15%–20% protein. During the washout period, a 
free diet was allowed. A complete 3-day food diary consisting of two working days 
and one holiday was kept three days before and during the last three days of the 
intervention periods to assess volunteer diet compliance. Food diaries were elaborated 
with dedicated software to decode foods (Nutritionist Pro 2.5, Axial System, Stafford, 
Texas), modified introducing the L-arginine contents, obtained from INRAN and 
USDA database, in about 800 different foods items. In table 2 is showed the 
composition of the diet in the subjects of the study. 
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Overnight fasting and during OGTT blood samples were collected at baseline and at 
the end of each intervention periods for serum/plasma biochemistries. In particular, 
samples for the evaluation of glucose, insulin, NOx and L-arginine levels were 
evaluated at 0, 30, 60, 90, and 120 minutes. c-GMP levels were evaluated at 0, 60, 90 
and 120 minutes. Further, samples for the measurement of plasma glucose and serum 
insulin levels were drawn at 0, 30, 60, 90, and 120 minutes and fasting proinsulin, 
ADMA, MMP-9, VEGF-α, SCF (sKit-L), SDF-1α levels were also evaluated. 
Basal blood pressure was taken in supine position after 10 min of rest, and the mean of 
two measurements was used as the value. Forearm blood flow (FBF) was measured by 
strain-gauge venous occlusion plethysmography. Before any measurement was taken, 
the hand circulation was occluded using a wrist cuff inflated to 240 mmHg. Baseline 
blood flow was calculated as the mean of at least three values. Reactive hyperaemia 
(endothelium-dependent vasodilation) was measured after the release of a 5-min 
arterial occlusion, produced by inflating a standard sphygmomanometer cuff on the 
upper arm to 100 mmHg above systolic blood pressure (SBP). These measurement 
were performed at basal and every 60 min until the end of the study. Body weight, fat 
mass and fat free mass distribution was evaluated by bioimpedenziometry using 
TANITA body fat analyzer (Tanita, Tokyo, Japan). The study design is reported in 
figure 1. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: study design 
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4.1.3 Endothelial progenitor cell  isolation and culture 
Circulating EPCs were enumerated by flow cytometry as positive cell population to 
CD34 and KDR expression markers using a hierarchical gating strategy to count cells 
negative for CD45 marker or expressing only very low levels (CD45dim). Briefly, 100 
µL peripheral blood was incubated with the following monoclonal antibodies: PE-
conjugated anti-human CD34 (BD, Franklin Lakes, NJ), allophycocyanin-conjugated 
anti-human KDR (R&D Systems, Minneapolis, MN), and PE-Cy7–conjugated anti-
human CD45 (Beckman Coulter, Brea, CA). After incubation, 100 µL Flow-Count 
beads (Beckman Coulter) was added to the stained whole blood. To avoid the loss of 
cells and/or counting beads, a lyse-no-wash technique was used as follows: 
erythrocytes were lysed with ammonium chloride buffer (155 mmol/L ammonium 
chloride, 10 mmol/L potassium bicarbonate, and 0.1 mmol/L EDTA), and the sample 
was analyzed immediately on a FACSCanto II flow cytometer, equipped with 
FACSDiva software (BD Biosciences, San Jose, CA). The data analyses were 
processed with FCS Express (De Novo Software, Los Angeles, CA), and the number of 
CD45dimCD34+KDR+ was expressed as number of cells per million of events. 
The number of colony-forming-units of EPCs was measured as described by Hill et al. 
(Hill JM, 2003). Peripheral-blood mononuclear cells were isolated by Ficoll density-
gradient centrifugation. Recovered cells were resuspended in growth medium (M 199 
Sigma-Aldrich, St. Louis, MO USA), supplemented with 20% Fetal Bovine Serum 
(FBS), 100 U/ml penicillin, 100 µg/ml streptomycin) and plated on endothelial cell 
attachment factor coated dishes (ECAF, Sigma-Aldrich, St. Louis, MO USA)  After 
48h, the no adherent cells were collected, sedimented by centrifugation, resuspended in 
culture medium and reseeded at 1×106/well in 24-well plates previously coated with 
endothelial cell attachment factor. Adherent cells were cultured for 7 days. At the end 
of culture, the number of colonies formed in 12 wells for each sample was counted. 
4.1.4 Gene expression 
Total RNA was isolated from the colonies formed on day 7 using the RNeasy Mini Kit 
(QIAGEN, Valencia, CA) with on-column DNase I digestion. Next, 2 µg total RNA 
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from each sample were reverse transcribed using superscript VILO cDNA synthesis kit 
(Invitrogen, Carisbad, CA, USA). Quantitative relative real-time PCR was used to 
measure the expression of eNOS and Akt genes. The PCR mix for SYBR Green assay 
was prepared using 10 uL SYBR Green PCR Master Mix (Applied Biosystems, Foster 
City, CA), 1 uL (1 pmol) sense primers, 1 uL (1 pmol) antisense primers, and 100 ng 
cDNA in a final reaction volume of 20 uL. The real-time PCR was performed in a 
Model 7900HT Fast Real-Time PCR System (Applied Biosystems Foster City, CA) 
under the universal cycling conditions consisting of one cycle at 50°C for 2 min, one 
cycle at 95°C for 10 min, and 40 cycles at 95°C for 15 s and at 60°C for 1 min. At the 
end of the real time PCR a CT  value (cycle threshold) is obtain for each sample. The 
level of β-actin expression (housekeeping gene), was used to normalize the amount of 
cDNA added to each reaction to obtain ∆CT value (difference between gene target CT 
value and β-actin CT value). Then the difference between ∆CT of each sample and ∆CT 
of the endogenous control (∆∆CT) is used in the final formula 2 −∆∆CT  to calculate gene 
expression levels.  
4.1.5 Laboratory measurements 
Glucose, total cholesterol, HDL-cholesterol and triglyceride levels were measured with 
spectrophotometric methods adapted to the Cobas MIRA using commercial kits (ABX, 
Rome, Italy). Insulin, proinsulin, SCF (sKit-L), MMP-9, ADMA, SDF-1α and VEGF-
α  levels were assayed by ELISA commercial kits (Insulin ELISA, Mercodia, Uppsala, 
Sweden;  Proinsulin ELISA, DRG, Marburg, Germany; MMP-9, Amersham 
Biosciences, Freiburg Germany; ADMA, Diagnostika GMBH Hamburg Germany, 
SDF-1α and SCF (sKit-L) R&D Systems Abingdon UK; VEGF-α, eBioscience, 
Vienna, Austria ). NOx levels were evaluated by metabolic end product measurement; 
i.e., nitrite and nitrate, using enzymatic catalysis coupled with the Griess reaction. The 
c-GMP levels were measured by ELISA (Cyclic GMP, Assay Designs, Ann Arbor, MI, 
USA). L-arginine was extracted from plasma samples using cation-exchange Strata 
SCX 100-mg columns (Phenomenex) and assayed by high-performance liquid 
chromatography (Pi, J).  
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4.1.6 Chemical analysis 
Biscuits’ proximate composition was assessed by AOAC methods (AOAC, 1975); 
soluble and insoluble dietary fiber was assessed by the enzymatic–gravimetric 
procedure (Prosky L, 2000), and carbohydrates were evaluated as simple sugars 
(Zygmunt LC, 1982) and total starch (Champ M, 1992). L-arginine content was 
assessed by HPLC (Cunico R, 1986).  
4.1.7 The software to decode foods  
Several softwares to decode foods are present, but we could not find appropriate 
software that could decode the micronutrients content, in particular the aminoacids 
contents. Therefore we decide to customize well-known software (Nutritionist Pro 2.5, 
Axial System, Stafford, Texas) by introducing the contents of all amino acids for more 
than 800 different foods, obtained from INRAN and USDA database items. When the 
modified software was ready, we analyzed the content of L-arginine in our patient’s 
diet. This software gives the possibility to analyze the food daily composition of diet, 
through this application we could known the energy intake, the composition of 
macronutrients and micronutrients. 
4.1.8  Statistical analysis 
All values are expressed as Mean±SD at each time interval. The patients’ response to 
the biscuit intervention was quantified as the difference between the values obtained at 
the end versus the beginning of the each food preparation intervention period. The 
groups were defined by the sequence of biscuit administration; i.e., the group that 
received the L-arginine-enriched biscuits first followed by the placebo biscuits was 
compared with the group that was fed the biscuits in reverse order. Differences 
between groups were evaluated by paired data student-T-test; a p value of less than 
0.05 was taken to indicate a significant difference. All analyses were performed using 
Statistical Package for Social Science (SPSS) version 15.0 software (SPSS Inc., 
Chicago, Illinois).   
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4.2 RESULTS 
4.2.1 Proximate composition 
In the following table (Table 3) is reported  the proximate composition (% wet weight) 
of the products administered during the study.  
(%ww) Arginine 
enriched Biscuit  
Placebo 
Biscuit 
Water  17.8      18.4 
Ash 1.3        1.4 
Protein 6.4*        7.4 
Starch 34.8      39.8 
Sugars 6.9        8.7 
Fat  12.5      14.6 
Dietary fiber  7.2        7.4 
Arginine 11.3         nd 
Energy (Kcal) 
                  (KJ) 
305  
         (1276) 
      350  
     (1486) 
Table 3: proximate composition of tested biscuits. 
*protein content has been estimated from total N content minus N from Arginine. 
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During a test, the subjects consumed a 60g (180 kcal) portion of the L-arginine-
enriched biscuits containing 6.6g L-arginine, 25.0 g carbohydrates, 3.8 g protein, 7.5 g 
fat and 4.3 g dietary fiber. 
4.2.2 Metabolic variables 
In the group receiving L-arginine-enriched biscuits, fasting L-arginine levels were 
quite double compared to the group receiving biscuits non containing L-arginine 
(117.8±26.9 vs  59.3±21.6 µmol/l; p<0.001) (Figure 2A), while the plasmatic levels of 
ADMA were lower in the group receiving the biscuits containing L-arginine as 
compared to the group receiving the biscuits not containing L-arginine (ADMA 
0.27±0.07 vs 0.32±0.06 µmol/l; p< 0.004) (Figure 2B). We, also, calculated the L-
arginine/ADMA ratio and we found that it was higher in the group receiving biscuits 
containing 6.6 g of L-arginine than  in the group receiving biscuits non containing L-
arginine (436.3 17.7 vs 185.3 27.9; p<0.001). (Figure 2C). 
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Figure 2: A. Fasting L-arginine levels in subjects receiving the L-arginine-enriched biscuits  
(black histograms) and in subjects receiving placebo biscuits (white histogram). B. Fasting 
ADMA levels in subjects receiving the L-arginine-enriched biscuits (black histograms) and 
in subjects receiving placebo biscuits (white histogram). C. Ratio of L-arginine/ADMA levels 
in subjects receiving L-arginine-enriched biscuits (black histograms) and in subjects 
receiving placebo biscuits (white histogram). Data are presented as Mean±SD. 
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The evaluated increase of L-arginine availability in treated subjects corresponded to a 
significant increase in nitric oxide (NOx) and cGMP levels during OGTT. In particular, 
nitric oxide (NOx) and cGMP plasma levels were significantly higher in the group 
receiving biscuits with L-arginine as compared to the group receiving placebo biscuits 
(Figures 3A and 4A). Area under the curve (AUC) and incremental area under the 
curve (∆AUC), calculated geometrically for NOx and cGMP respectively, were also 
evaluated. AUC NOx (1250±200 vs 730±185 µmol/L* 120 min; p<0.05) and ∆AUC 
cGMP (2495±329 vs 1742±155 pmol/mL* 120 min; p<0.05) were significantly 
increased when compared to the group receiving placebo biscuits (Figure 3B and 4B).   
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Figure 3: A. Patterns of plasma NOx levels during OGTT in subjects receiving L-arginine-
enriched biscuits (black circles) and in subjects receiving placebo biscuits (white circles). B. 
Comparison of the areas under the curve for NOx (AUC NOx) during the OGTT in subjects 
receiving L-arginine-enriched biscuits (black histograms) and in subjects receiving placebo 
biscuits (white histogram), calculated using the trapezoidal rule. Data are presented as 
Mean±SD. 
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Figure 4: A. Patterns of plasma cGMP levels during OGTT in subjects receiving L-arginine-
enriched biscuits (black circles) and in subjects receiving placebo biscuits (white circles). B. 
Comparison of the incremental areas under the curve for cGMP (∆AUC cGMP) during OGTT 
in subjects receiving L-arginine-enriched biscuits (black histograms) and in subjects receiving 
placebo biscuits (white histogram), calculated using the trapezoidal rule. Data are presented as 
Mean±SD. 
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Post-ischemic blood flow significantly (p<0.01)  increased in the group receiving L-
arginine enriched biscuits as compared to the group receiving placebo, suggesting a 
functional effect of the amino acid added to the food product (Figure 5). 
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Figure 5: Incremental increase from basal levels in post-ischemic blood flow in subjects 
receiving the two different treatment conditions. Data are presented as Mean±SD. 
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The endothelial progenitor cells, evaluated as both KDR/CD34 circulating cells than as 
colony-forming units at the end of the cell culture, were higher in the group receiving 
the biscuits containing L-arginine as compared to the group receiving placebo biscuits 
(KDR/CD34 291.6±134.7 vs 162.9±81.4; p<0.001; CFUs 8.3±6.2 vs 2.9±2.3; p<0.01) 
(Figure 6A and B).  
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Figure 6: A. KDR/CD34 circulating cells in subjects receiving L-arginine-enriched biscuits 
(black histograms) and in subjects placebo biscuits (white histogram). B. Colony-forming-units 
(CFUs) in subjects receiving L-arginine-enriched biscuits (black histograms) and in subjects 
receiving placebo biscuits (white histogram). Data are presented as Mean±SD. 
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Very interesting, the molecules involved in the EPCs mobilisation and homing, 
evaluated both as peripheral plasmatic levels and as gene expression levels, were 
higher in the group receiving L-arginine-enriched biscuits than in the group receiving 
placebo biscuits. In particular VEGF-α was 51.5±17.2 vs 38.1±10.9 pg/ml; p<0.05; 
SCF (sKit-L) 1179.1±161 vs 1140.1±163 pg/ml: p< 0.05; MMP-9 29.2±12.9 vs 
19.4±7.7 ng/ml; p<0.01; SDF-1α 2931.2±510 vs 2561.3±349 pg/ml; p<0.01, 
respectively (Figure 7A-D).  While the expression of Akt and eNOS genes were 
2.1±2.2 vs 1.6±2.2 ∆∆ct; p<0.01 and 3.3±2.9 vs 1.1±0.9 ∆∆ct; p<0.05 respectively 
(Figure 8A and B). 
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Figure 7: A. Fasting VEGF-α levels in subjects receiving L-arginine-enriched biscuits (black 
histograms) and in subjects receiving placebo biscuits (white histogram). B. Fasting SCF (sKit-
L) levels in subjects receiving L-arginine-enriched biscuits (black histograms) and in subjects 
receiving placebo biscuits (white histogram). C. Fasting MMP-9 levels in subjects receiving the 
L-arginine-enriched biscuits (black histograms) and in subjects receiving placebo biscuits 
(white histogram). D. Fasting SDF-1α levels in subjects receiving the L-arginine-enriched 
biscuits (black histograms) and in subjects receiving placebo biscuits (white histogram). Data 
are presented as Mean±SD. 
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Figure 8: A. Akt gene expression levels (calculated with the formula 2-∆∆CT; see materials and 
metods 4.1.4) in subjects receiving L-arginine-enriched biscuits (black histograms) and in 
subjects receiving placebo biscuits (white histogram). B. eNOS gene expression levels in 
subjects receiving L-arginine-enriched biscuits (black histograms) and in subjects receiving 
placebo biscuits (white histogram). Data are presented as Mean±SD. 
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Interestingly glucose levels and AUC of glucose were significantly lower in the group 
receiving the biscuits containing L-arginine as compared to the group receiving the 
Placebo biscuits, even if insulin levels were not significantly different (Figure 9 A-D).  
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Figure 9: A. Patterns of plasma glucose levels during OGTT in subjects receiving L-arginine-
enriched biscuits (black circles) and in subjects receiving placebo biscuits (white circles). B. 
Comparison of the areas under the curve for glucose (AUC glucose) during the OGTT in 
subjects receiving L-arginine-enriched biscuits (black histograms) and in subjects receiving 
placebo biscuits (white histogram), calculated using the trapezoidal rule. C. Patterns of plasma 
insulin levels during OGTT in subjects receiving the L-arginine-enriched biscuits (black circles) 
and in subjects receiving placebo biscuits (white circles).  D. Comparison of the areas under the 
curve for insulin (AUC insulin) during the OGTT in subjects receiving L-arginine-enriched 
biscuits (black histograms) and in subjects receiving placebo biscuits (white histogram), 
calculated using the trapezoidal rule. Data are presented as Mean±SD. 
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In the  group receiving L-arginine enriched biscuits body weight was reduced by 
2.57±0.33 kg as compared to a body weight reduction of 1.37±0.34 assessed after 14 
days biscuits without L-arginine (p<0.05). Interestingly, during the 14 days of food 
intervention with L-arginine, quite all the body weight changes related to a reduction of 
fat mass (2.02±0.52 kg vs 0.70±0.50 kg ; p<0.01). Conversely, no differences were 
demonstrated in the loss of fat free mass between the two groups (figure 10). 
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Figure 10: Changes in body weight, fat mass and fat free mass as compared to baseline in 
subjects receiving L-arginine-enriched biscuits (black histograms) and in subjects receiving 
placebo biscuits (white histogram). To evaluate changes in body weight compositions, patients’ 
response to food interventions was calculated as the difference between the values obtained at 
the end and at the beginning of the each food preparation intervention period. Data are 
presented as Mean±SD. 
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4.3 DISCUSSION 
In the present study, a new food product, in form of a biscuit obtained by a novel 
technological process (aggregation by sonication at low temperature), comprising a 
high content in L-arginine and a low content in sugars and proteins, was used in obese 
subjects with impaired glucose tolerance and metabolic syndrome.  
It is noteworthy that the present L-arginine-enriched biscuit composition is in 
accordance with current dietary guidelines.  
Regarding total carbohydrates content, the food product appears interesting not only 
for its low carbohydrate content, but also for the quality of carbohydrate itself. In fact, 
in line with current dietary guidelines supporting a limited sugars intake up to 12% of 
daily energy in favour of complex carbohydrates (starch), L-arginine-enriched biscuit 
contains low amount of sugars (about 6.9 % ww) and mainly starch from whole cereals 
(35 % ww). This feature is favourable in the light of the potential low glycemic impact 
induced by whole-grain cereal starch and it is particularly advantageous since the 
present food preparation was used in subjects at high risk of cardiovascular disease.  
The interesting results on an amelioration of endothelial function, insulin sensitivity 
and reduction of adipose tissue are in line with previous results. Fu et al. studied 
Zucker Diabetic fatty rats submitted to a dietary supplementation of drinking water 
containing L-arginine (1.51%) or alanine (2.55%, isonitrogenous control) for 10 weeks. 
Arginine supplementation significantly reduced weight of retroperitoneal and 
epididymal adipose tissue by 45 and 25%, respectively, as well as circulating levels of 
glucose by 25%, triglycerides by 23%, free fatty acids by 27%, homocysteine by 26%, 
ADMA by 18-21% and leptin by 32%. Further, in this manuscript results of the 
microarray analysis indicated that Arginine supplementation increased adipose tissue 
expression of key genes responsible for fatty acid and glucose oxidation, NO synthase-
1, AMP-activated protein kinase and peroxisome proliferator-activated receptor 
gamma coactivator-1 alpha (Fu WJ).   
In the same line the results of amelioration of endothelium-dependent vasorelaxation 
were previously reported. Hayashi et al. demonstrated rabbits fed a high-cholesterol 
diet that an 12 weeks oral administration of L-arginine plus L-citrulline, either alone or 
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in combination with antioxidants, caused a marked improvement in endothelium-
dependent vasorelaxation and blood flow, dramatic regression in atheromatous lesions, 
and decrease in superoxide production and oxidation-sensitive gene expression 
(Hayashi T). In healthy young subjects L-arginine infusion at 10, 20, 40, and 60 
mg/min increase forearm blood flow dose dependently, moreover this effect was 
amplified by the simultaneous infusion of acetylcholine ( Imaizumi T). Also Bode-
Boger et al. investigated healthy volunteers and the effect of an intravenous infusion of 
L-arginine (a dose of 30 g for 30 min) on blood pressure; they showed that L-arginine 
reduced blood pressure and that this effect was strikingly evident for diastolic pressure 
(Boger RH). Creager et al. demonstrated that in hypercholesterolemic patients an acute 
administration of L-arginine (10 mg/kg/min i.v.) was able to induce an improvement of 
L-arginine blood vessels endothelium-dependent vasodilation (Creager MA). Egashira 
et al. examined the effect of L-arginine on endothelium-dependent coronary 
vasodilation in patients with microvascular angina throughout an intracoronary 
infusion of L-arginine (50 mg/mm) on acetylcholine-induced coronary vasomotion. L-
arginine was able to improve endothelium-dependent vasodilation of coronary 
microcirculation in these patients (Egashira K). An acute infusion of low dose of L-
arginine infusion (0.125 g/min) at dose not able to stimulate the insulin-induced 
endothelial dependent vasodilation, increased forearm blood flow, cyclic-GMP forearm 
release and decreased endothelin-1 levels in healthy subjects. As shown by our group, 
in patients affected by microvascular angina similar amount of L-arginine infusion 
increased forearm blood flow, circulating NOx and forearm cGMP release and 
decreased endothelin-1 levels and systolic and diastolic pressure. Moreover, the pre-
infusion of low-dose of L-arginine restored the endothelin-1, NOx, forearm cGMP 
release responses after insulin bolus in these patients (Piatti P).  
In addition, when endothelial function is impaired as in healthy very old age 
subjects, oral L-arginine supplementation was able to improved endothelial 
vasodilation (Bode-Boger SM). Clarkson et al. found that L-arginine addition 
improved endothelium-dependent vasodilation compared to placebo in a double blind 
cross over study with 4 weeks L-arginine supplementation (7 g three times a day) or 
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placebo in hypercholesterolemic young adults (Clarkson P). Hambrecht et al. studied 
the effect of L-arginine (8 g daily) and physical exercise in patients with chronic heart 
failure. After 4 weeks both L-arginine than physical exercise were able to improve 
endothelium dependent vasodilation, but when associated L-arginine plus exercise 
produced an additive beneficial effects on endothelium dependent vasodilation 
(Hambrecht R). Finally, Palloshi et al. demonstrated that a chronic administration of L-
arginine (4 weeks, 6 g daily) in patients with hypertension and microvascular angina 
determined an improvement of endothelial function and a significant amelioration of 
symptoms (Palloshi A).  
In 1992, Vallance et al. first described the presence of asymmetric dimethylarginine 
(ADMA) as an endogenous inhibitor of eNOS in human plasma and urine (Vallance 
P). ADMA inhibits vascular nitric oxide production within the concentration range 
found in patients with vascular disease. Elevated ADMA concentrations are present in 
patients with hypercolesterolemia, hyperhomocisteinemia, diabetes mellitus, insulin 
resistance, atherosclerosis and hypertension, cardiovascular disease and chronic heart 
failure (Abbasi F). In the present study, the administration of L-arginine was able to 
decrease ADMA levels, increasing L-arginine/ADMA levels. 
A quite important and new result of the present study was that we were able to 
demonstrate, for the first time, that L-arginine enriched biscuits increased the number 
of endothelial progenitor cells evaluated both as circulating peripheral cells and as 
colony-forming-units after cell culture. One possible explanation could  be related to a 
decrease in glucose levels and to an improvement of insulin sensitivity and secretion  
in subjects receiving L-arginine enriched biscuits compared to placebo. In fact,  it has 
been demonstrated that disorders in glucose regulation are associated with 
abnormalities in EPC biology, including their reduced circulating number, defective 
mobilization from bone marrow and impaired functional properties such as their 
capacity to mediate endothelial repair. Fadini et al.,  in 2006, showed a reduced number 
of EPCs in individuals with impaired glucose tolerance compared with those normal 
glucose regulation and in a different study they displayed that EPCs negatively 
correlated with components of metabolic syndrome and with HOMA-IR, a score of 
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insulin resistance. (Fadini GP 2006). EPCs were also found to be lower in another 
study of obese men with the metabolic syndrome compared with non-obese healthy 
controls (Westerwell PE). Thus, reduced circulating EPCs may be attributable to a 
number of factors, including defective mobilization, decreased proliferation and 
shortened survival in the circulation (Aicher A, 2003; Aicher A, 2004; Hristov M). 
Another explanation which could concur with alteration in glucose metabolism/insulin 
resistance is that reduced NO bioavailability impairs EPC mobilization and function in 
experimental models. (Balletshofer BM; Duncan ER; Wheatcroft SB; Steinberg HO). 
Insulin resistance is closely associated with abnormalities in NO bioavailability and 
PI3K/Akt signalling, both of which play a crucial role in EPC mobilization from the 
bone marrow (Aicher A; Hristov M; Dimmeler S; Thum T; Werner C; Urao N) through 
the activation of eNOS. This is related to the fact that insulin resistance impairs the 
insulin binding to its receptor, impairing the cascade of protein phosphorilation, 
involving the signalling intermediates (IRSs, PI3K and Akt). The alteration of the 
pathway results in both, altered traslocation of GLUT4 to the cell membrane, which 
mediates glucose uptake,  and reduced phosphorilation of eNOS culminating in 
increased NO production.  
The results of  increased expressions of eNOS and Akt genes in EPCs from subjects 
receiving L-arginine enriched biscuits are, in our opinion, of particular interest, 
suggesting that L-arginine is able to enhance the expression levels of genes involved, 
non only in metabolic and endothelial function, but also in EPCs mobilization and 
function. Physical exercise,  statins also mobilize EPCs from the bone marrow via a 
partially NO-dependent mechanism, which is abolished by concomitant treatment with 
the NO synthase inhibitor l-NAME (NG-nitro-l-arginine methyl ester) (Laufs U, 1998; 
Laufs 2004). Fadini et al. reported that DDp-4 inhibitor, Sitagliptin, was able to 
increase EPCs cells by the role of SDF-1α. (Fadini GP, 2010). Also in the present 
study, SDF-1α levels increased suggesting that L-arginine could follow, at least in part, 
the same pathway of DPP-4 inhibitor in increasing EPCs levels. 
Finally, we were able to demonstrate that L-arginine enriched biscuits is able to 
increase VEGF-α, MMP-9 and SCF (sKit-L), which are peripheral markers of EPCs 
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mobilization. In fact,  mobilization of EPCs from the bone marrow into the circulation 
occurs in response to growth factors and cytokines, including VEGF (vascular 
endothelial growth factor), SDF-1α (stromal-cell-derived factor-1α) (Aicher A, 2005). 
Both VEGF and SDF-1α up-regulate bone marrow MMP-9 (matrix metalloproteinase-
9) activity, which cleaves the progenitor cell membrane-bound kit ligand, allowing 
mobilization of progenitors into the bone marrow vascular zone (Aicher A, 2005). 
Nitrosylation of MMP-9 by NO, released from bone marrow stromal cells, is required 
for VEGF-stimulated EPC mobilization (Aicher A, 2005). Chemokine signalling plays 
a major role in directing circulating progenitor cells to sites of injury.  
An interesting result of this study, conducted in obese subjects with IGT and MS, was 
the significant decrease of body weight in the group receiving the biscuits added with 
L-arginine which was quite completely accounted by a loss of fat mass. These results 
corroborates previous data in which oral administration of L-arginine added to a 
structured physical activity and hypo caloric regimen for 21 days was able to decrease 
body weight mainly as a reduction of fat mass sparing fat free mass in obese type 2 
diabetic subjects (Lucotti P, 2006). The strength of the present study is that the loose of 
body weight was achieved without the help of a structured program of physical activity 
in patients quite sedentary. Moreover, the obese subjects admitted to take the biscuits 
with L-arginine loosed more weight and fat mass that the same subjects taking the 
biscuits without the addition of L-arginine. Recently Monti LD et al. performed a 
mono-centre, randomized, double-blind, parallel-group, placebo-controlled, phase III 
trial (named l-arg trial). In this study, 144 individuals, affected by impaired glucose 
tolerance (IGT) and metabolic syndrome (MS), received 6.4g/day of l-Arg, or placebo 
for 18 months plus a 12-month extended follow-up period after study drug termination, 
in order to prevent or delay type 2 diabetes and to normalize glucose tolerance in 
individuals at high risk for type 2 diabetes. The results showed that the 
supplementation of l-arg for 18 months does not significantly reduce the incidence of 
diabetes but does significantly increase regression to NGT. (Monti LD, 2012). 
The results of the present study are particularly interesting mainly on the action of L-
arginine on EPCs, Akt/eNOS activation, EPCs increment and cytochine/chemokine 
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modulation. Interestingly, the results are similar to those obtained with a 
pharmacological approach using a DPP-4 inhibitor, Sitagliptin in patients with type 2 
diabetes mellitus. Since in the long-term study, L-arginine had no adverse events, as 
demonstrated by Monti et al.(2012), it is possible to suggest the use of this food 
product in subjects with glucose intolerance and cardiovascular disease, in addition to a 
usual standard care. The results of this study need to be reproduced in an increased 
number of subjects for a prolonged period of time. However, if these results are 
replicated a new nutritional approach could be easily achieved, which is safe, cost-
saving and could be utilized by a large number of subjects.  
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5. CONCLUSION 
In conclusion the study results reveal that consumption of L-arginine-enriched biscuits 
with low sugar content for 14 days was safe and useful for improving endothelial and 
vascular function, insulin sensitivity and body mass composition.  
As a new hypothesis of our study, we evaluated the role of endothelial progenitor cells 
in state of insulin resistance and after a nutritional intervention. In particular, we 
evaluated Akt/eNOS pathway in EPCs and we demonstrated that L-arginine added 
biscuit was able to restore EPC mobilization and differentiation properties. Moreover, 
L-arginine-enriched biscuits improved glucose metabolism, blood flow and decreased 
body weight and fat mass in subjects with IGT and MS.  
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VARIANTI DI ENOS E PREVALENZA DI DIABETE TIPO 2 IN UNA 
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Precedentemente abbiamo riportato un’associazione genetica fra 2 SNPs di eNOS con 
diabete tipo 2 (DMT2) e sindrome metabolica in pazienti diabetici di tipo 2. Nel 
presente studio, abbiamo valutato l’effetto di 4 SNPs di eNOS sulla regolazione del 
metabolismo glucidico e sulla secrezione insulinica in soggetti ad alto rischio di 
sviluppare la patologia, first degree relatives (FDR) di DMT2. La popolazione 
consisteva di 1274 soggetti (M 813 e F 461) con età media 57.5±11.5 anni. Circa il 
50% dei soggetti presentava uno o più fattori diagnostici per sindrome metabolica. 
Variabili cliniche e metaboliche sono state misurate al basale e durante OGTT. La 
discriminazione allelica è stata valutata su 4 SNPs di eNOS: rs1799983 sull’esone 7, 
rs753482 sull’introne 18, rs743506 sull’introne 19 e rs373001020 sull’introne 20. La 
presenza dei quattro alleli mutati associava con aumentati livelli di glicemia e di 
insulinemia durante OGTT, con un incremento di HOMA-IR e una riduzione del 
Matsuda e Disposition Index. La prevalenza di DMT2 era significativamente 
aumentata nei portatori di alleli mutati rispetto ai portatori di alleli non mutati; con un 
OR per DMT2 di 2.55 (CI 95%:1.78-3.66) per l’allele mutato di rs1799983 e di 3.42 
(CI 95%: 2.32-5.05) per l’allele mutato di rs753482. Sono stati definiti quattro aplotipi 
maggiori (GAAT, TCGC, TAAT e GCGC). Haplo TCGC aveva una frequenza 
maggiore in soggetti con impaired glucose regulation (IGT+DMT2 all'OGTT), 
mostrando livelli glicemici e insulinemici durante OGTT significativamente più 
elevati, un aumentato HOMA-IR e ridotti Matsuda e Disposition Index rispetto agli 
altri aplotipi. In conclusione, la presenza di 4 SNPs di eNOS sembra essere associata 
con una maggiore prevalenza di impaired glucose regulation in una coorte di soggetti 
non diabetici noti, FDR di DMT2 
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Il background genetico che causa diabete mellito tipo 2 e insulino resistenza non è stato 
ancora completamente definito. Il nostro gruppo ha riportato un’associazione genetica 
fra 2 polimorfismi di eNOS (Glu298Asp rs1799983G>T e rs753482-A>C) con diabete 
mellito tipo 2 e sindrome metabolica in una piccola coorte di pazienti diabetici. Nel 
presente studio, abbiamo valutato l’effetto di 4 SNPs di eNOS sulla suscettibilità di 
presentare un’alterata regolazione del metabolismo glucidico (alterata tolleranza ai 
carboidrati o diabete mellito di tipo 2 dopo carico orale di glucosio (OGTT) e sulla 
secrezione insulinica in soggetti ad alto rischio di sviluppare la patologia, i.e. parenti di 
I grado di soggetti diabetici di tipo 2, non diabetici noti. La popolazione consisteva di 
1274 soggetti (M 813 e F 4619 con età media 57.5±11.5 anni, BMI  27.6±4.8 kg/m2, 
pressione sistolica 127±15 mmHg e pressione diastolica 79±9 mmHg. Circa il 50% dei 
soggetti presentava uno o più fattori diagnostici per sindrome metabolica. Variabili 
metaboliche, di sensibilità e di secrezione insulinica e di funzione endoteliale sono 
state misurate al basale e durante OGTT. La discriminazione allelica è stata valutata su 
4 SNPs di eNOS (rs1799983 in posizione 150327044 (Glu298Asp) sull’esone 7, 
rs753482 (A/C) in posizione 150337316 sull’introne 18, rs743506 (A/G)  in posizione 
150337848 sull’introne 19 e rs373001020 (T/C) in posizione 150338348 sull’introne 
20. La presenza dei quattro alleli mutati associava significativamente con aumentati 
livelli di glicemia e di insulina durante OGTT, con un incremento dei livelli di HOMA-
IR e un riduzione della sensibilità insulinica durante OGTT (Matsuda Index), e 
un’alterata secrezione insulinica valutata come first phase insulin secretion/HOMA-IR 
ratio. La prevalenza del diabete mellito tipo 2 era significativamente aumentata con 
valori fra il 18.5 e il 20.5% nei portatori di alleli mutati rispetto al 5.5-7.3% per i 
portatori di alleli non mutati; con un OR di presentare diabete mellito tipo 2 dopo 
OGTT  di 2.553 (CI 95%:1.782-3.656) per l’allele mutato di rs1799983 e di 3.419 (CI 
95%: 2.316-5.047) per l’allele mutato di rs753482. Sono stati definiti quattro aplotipi 
maggiori (GAAT, TCGC, TAAT e GCGC) mentre altri aplotipi rari (frequenza 
inferiore al 3%) sono stati raggruppati determinando ~8% del totale mentre i due 
aplotipi haplo.GAAT e haplo.TCGC, determinavano ~80% del totale. Haplo.TCGC ha 
dimostrato un aumento di 2 volte nella prevalenza di diabete di tipo 2 rispetto a 
haplo.GAAT con un OR di 2.100 (CI 95%: 1.725-2.557, p< 2.8 x 10-12). I livelli 
glicemici e insulinemici durante OGTT erano significativamente più elevate nei 
soggetti con haplo.TCGC rispetto a haplo.GAAT and haplo. TAAC (p<0.001), in 
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presenza di aumentato HOMA-IR e ridotti livelli di Matsuda index e first phase insulin 
secretion/HOMA-IR ratio rispetto a haplo.GAAT (p<0.001). In conclusione, la 
presenza di 4 SNPs di eNOS sembra essere associata con una maggiore prevalenza di 
diabete mellito tipo 2 in una coorte di soggetti non diabetici noti ma ad alto rischio di 
sviluppare la patologia, i.e. parenti di I grado di soggetti diabetici di tipo 2. 
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Nitric oxide (NO) plays a key role in vascular homeostasis and is produced by 
endothelial NO synthase (eNOS), encoded by NOS3 gene. We previously reported the 
genetic association between NOS3 rs753482-A>C polymorphism on intron 19 and 
coronary artery disease (CAD). In the attempt of conferring functional implication to 
the rs753482-A>C polymorphism, we investigated its influence on transcript 
maturation. 
We identified three alternatively spliced NOS3 isoforms lacking exon 20 or 21 or both. 
All these alternative splicing events caused a frame shift and a premature stop codon 
insertion. Interestingly, one of the resulting truncated isoform, the transcript variant 
skipping exons 20-21, is translated in a novel and stable truncated form of eNOS (D20-
21 eNOS). This truncated eNOS displays increased basal NO production, is insensitive 
to calcium stimulation, and, upon heterodimerization with the full-length eNOS 
protein, exerts a dominant-negative effect on NO production. The D20-21 eNOS 
isoform is prevalent in carriers of the rs753482-C allele. Interestingly, CAD patients 
and healthy subjects carriers of the rs753482-C genotype are characterized by 
increased NO basal levels in peripheral blood and platelets, and negatively respond to 
oral glucose load by failing to increase NO synthesis following insulin wave. 
Furthermore, forearm vasodilation after reactive hyperemia is dramatically impaired in 
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rs753482-C carriers. Therefore, we propose that carriers of the rs753482-C genotype 
are subjects at risk for the broad group of disorders originating from dysfunctional 
endothelium. These data open to new intriguing perspectives for different diseases 
involving vasculature response to NO, though the molecular mechanisms of action and 
regulation of the D20-21 eNOS both in CAD patients and in 82C healthy subjects need 
further investigation. 
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Our group is mainly involved in the -Genetic of type 2 diabetes mellitus (T2DM), -
Inflammation and -Nutrition. We have a strict collaboration with the 
CardioThoracoVascular, Neurology, Translational Genomics Depts. We demonstrated 
that NOS3 82A/C polymorphism generates a novel and stable truncated eNOS with 
increased basal NO synthesis activity, failing to respond to calcium-ionomycin and 
insulin stimulation. We propose that the polymorphism, acting through the truncated 
isoform, gives endothelial dysfunction (ED) not only in cardiovascular (CV) patients 
but also in healthy subjects (HS). In the light of previous results, we evaluated a cohort 
of more than 1000 first degree relatives of T2DM, demonstrating that subjects carrying 
the polymorphism had a high degree of IR and  β-cell dysfunction and increased risk to 
develop T2DM. Since, it remains unclear whether in HS with normal glucose tolerance 
(NGT) different degrees of insulin resistance (IR) associates with a variation in the 
number of circulating EPCs, we demonstrated that reduced EPCs correlated with the 
cluster of abnormalities linked to the IR, suggesting a possible role for EPCs as early 
markers of glucose intolerance and CV risk. In another study, we observed that patients 
with limb ischemia carrying the polymorphism had an increased risk of major 
cardiovascular events that correlated with lower circulating EPCs. A translational 
aspect of our research is the evaluation of the effects of L-arginine, a precursor of nitric 
oxide by eNOS. In subjects with IGT and MS, the use of 6.4 g L-arg daily when added 
to lifestyle intervention for 18 months significantly ameliorated glucose metabolism, 
reverting IGT to NGT. The consumption of L-arginine added in biscuits with a low 
content in sugars and proteins for 14 days improved ED, IR and insulin secretion in HS 
with IGT and MS. Therefore, L-arginine enriched food may have a role in the dietary 
management of individuals at risk of T2DM  and CV. All in all, our data demonstrate 
that an eNOS polymorphism seems to have a functional effect giving increased ED and 
IR while L-arginine supplementation demonstrates beneficial effects on IR, 
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inflammation and ED. In both cases EPCs seem to have a predominant effects. 
Molecular mechanisms are actually under evaluation. 
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